Arcus Biosciences established a collaboration with Bristol-Myers Squibb and discussed study plans with the FDA on August 1, 2026.

The entities involved

• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• Arcus Biosciences →

  biopharmaceutical company

  Nothing else this week.

• Bristol-Myers Squibb →

  American pharmaceutical company

  • Bristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Mon 13:45
  • FDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.Mon 09:09

Related events

• Bristol-Myers Squibb and AstraZeneca announced a collaboration on advanced cancer drug development.Aug 18
• Bristol-Myers Squibb has taken ownership of Celgene's drug.Jun 7
• The FDA received information on June 27, 2025, regarding regulatory approval to streamline patient monitoring for a product involving Bristol-Myers Squibb.Jun 8
• FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.Aug 28
• Cocrystal Pharma and Bristol-Myers Squibb are competing for investment as healthcare companies.Sun 22:20